Health Economics›CNS melanoma›All lines of therapy

All lines of therapy

CNS melanoma · 5 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

Filters

Y-axis

Cost vs Efficacy · 3 points

Fully pricedPartial pricing

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
Ipilimumab and Nivolumab Variant #01 Partial	—	R 78 615	42d	—	29.2 mo	—	—	1
Dabrafenib and Trametinib Variant #01	—	R 52 791	28d	~10.7 mo	—	~12	~R 633 492 PFS proxy · indirect	6
Dabrafenib monotherapy Variant #01	—	R 26 396	28d	~5.5 mo	—	~6	~R 158 373 PFS proxy · indirect	4
Vemurafenib monotherapy Variant #01	—	R 13 464	28d	~7.2 mo	~15.5 mo	~8	~R 107 711 PFS proxy · indirect	4
Fotemustine monotherapy Variant #01 Partial	—	—	56d	—	~13.8 mo	—	—	1

5 of 5 regimens shown